Beta Technologies conducts first all-electric aircraft landing
(Reuters) - Beta Technologies became the first U.S. company to land an all-electric aircraft at an airport in the New York-New Jersey region, the company and port authorities said in Tuesday.
The flight to New York's John F. Kennedy International Airport flew 45 minutes with a pilot and four people, they said in a statement.
Transportation companies, including airlines, are looking to develop services using electric battery-powered aircraft that can take off and land vertically to ferry travelers for short city trips, allowing them to beat traffic.
In October, the Federal Aviation Administration finalized comprehensive training and pilot certification rules for flying air taxis, calling it "the final piece in the puzzle for safely introducing these aircraft in the near term."
In the same month, Beta raised $318 million in equity capital to fund production, certification, and commercialization of electric aircraft, bringing its total raised value to more than $1 billion.
The Vermont-based company was founded in 2017.
"After years of rigorous safety testing in all types of environments, we're proud to stand here with the Port Authority and the city of New York to demonstrate exactly how this aircraft can serve cities by easing congestion, reducing emissions, and increasing accessibility," Kyle Clark, CEO and founder of the privately held company, said in the statement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
9 minutes ago
- Time Business News
Best Electrical Services on the Sunshine Coast — Niche Electrical Group
When you're looking for dependable electrical work on the Sunshine Coast, you need a team that's experienced, licensed, and focused on safety. At Niche Electrical Group, we provide high-quality electrical services across residential, commercial, and industrial sectors — with a reputation for prompt, efficient solutions that last. From urgent electrical faults to major installations, our electricians handle every job with precision and care. Our standout offering? Specialised industrial electrical maintenance that ensures your critical systems operate safely and efficiently year-round. Why Locals Choose Niche Electrical Group As a Sunshine Coast-based company, we take pride in delivering electrical services that meet the specific needs of our local community. Our fully insured and qualified team has experience across all types of projects — from home renovations to factory fit-outs — always with a strong focus on safety, compliance, and customer satisfaction. We use the latest tools and high-quality materials to guarantee reliable results. Whether you're upgrading your home's lighting or planning a long-term industrial electrical maintenance strategy, you can count on us to get it right the first time. Electrical Services for Every Environment Residential Electrical Ensure your home is powered safely and efficiently with our full range of residential services: Custom lighting design and installs Switchboard upgrades Safety switch and smoke alarm installation Home security systems and smart automation General fault finding and compliance checks Need help fast? We also offer quick-response emergency services and preventative maintenance. Commercial Electrical Businesses need electrical systems they can rely on. We offer tailored solutions for: Shop and office fit-outs Network and data cabling LED lighting upgrades Test and tag compliance Switches, power outlets, and more Our electricians work to your schedule, delivering projects on time and within budget. The Sunshine Coast's Industrial Electrical Maintenance Experts For industrial clients, we offer complete industrial electrical maintenance services to help keep operations running without disruption. Industrial environments require robust, expertly maintained systems — and our team delivers exactly that. What Does Industrial Electrical Maintenance Involve? It's the regular servicing, repair, and inspection of electrical systems in plants, warehouses, and production facilities. We work on: Switchboards and control panels High-voltage motors and drives PLCs and automation systems Industrial lighting and HVAC Power distribution setups Emergency systems (UPS, generators) Our trained electricians ensure all work complies with WHS regulations and Australian electrical standards. Why Preventive Maintenance Matters Avoid Downtime : Catch issues early before they cause system failures : Catch issues early before they cause system failures Extend Equipment Life : Keep components running longer : Keep components running longer Boost Safety : Prevent electrical hazards with regular checks : Prevent electrical hazards with regular checks Cut Energy Waste : Identify and fix inefficiencies : Identify and fix inefficiencies Stay Compliant: Meet all local safety and wiring codes Available 24/7 for Emergency Electrical Work Power failures and unexpected issues don't follow a 9-to-5 schedule. That's why Niche Electrical Group is available around the clock to handle emergency situations. Whether it's your home, business, or industrial site, we respond fast to get things running again. Local Electricians You Can Trust We're proud to be part of the Sunshine Coast community — known for our honest advice, professional workmanship, and dedication to quality. From once-off callouts to long-term maintenance plans, Niche Electrical Group is ready to be your go-to electrical partner. Explore our full range of services and discover why more locals are turning to us for reliable industrial electrical maintenance and beyond. TIME BUSINESS NEWS
Yahoo
9 minutes ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Goldman Sachs pares risk after tariff move, braces for more uncertainty
By Saeed Azhar NEW YORK (Reuters) -Goldman Sachs has moderated its risk-taking since U.S. President Donald Trump's April tariff announcement, and the Wall Street bank is braced for more uncertainty, a top executive said. "We have moderated our risk positioning since April 2nd - I think that's a sensible thing for us to do," Goldman President John Waldron said in a podcast released by the investment bank on Thursday. "We're absorbing a lot of risk from our clients. We want to continue to do that, but we also, where we can, we (pare) our risk and stay a little bit closer to home." Goldman is readying for continued uncertainty in the coming months, which means keeping a greater liquidity cushion, he said. Financial markets have been turbulent since Trump's so-called "Liberation Day," when he announced plans to increase tariffs on trading partners. Waldron, who is widely seen as the likely successor to Goldman CEO David Solomon, said the tariff move was "very, very disruptive." Some companies are now starting to make business decisions based on assumptions that tariffs will be raised to a range of 10% to 15%, he said. "We're moving into now an adjustment phase, and you'll see, I think, some more decision-making on capital spend, M&A transactions, capital return, stock buybacks," Waldron said. The U.S. economy is still strong, backed by a solid labor market and consumer spending, he said. "All those factors in the U.S. to me lead to a likely scenario where we don't have a recession," he said. Meanwhile, Waldron warned investors were getting concerned about an unsustainable U.S. fiscal deficit. "The bond market is starting to be heard, and I hope that gets some attention in the halls of Congress," he said. Rating agency Moody's cut the pristine U.S. sovereign credit rating by one notch last month, the last of the major ratings agencies to downgrade the country, citing concerns about the nation's growing $36 trillion debt pile. The biggest question for markets is the path of interest rates, particularly in the long term, Waldron said. "We're seeing a lot of increase in duration in the rate curves in the United States and Japan and many other countries - and I think that could be a brake on economic growth," he said.
